Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

Core Insights - Arch Biopartners Inc. has announced new findings identifying interleukin-32 (IL-32) as a novel cytokine associated with lipid droplets that may contribute to tubular injury and inflammation in diabetic kidney disease (DKD) [1][2][3] Research Findings - The research indicates that during DKD, kidney cells accumulate lipid droplets coated with IL-32, which is believed to drive kidney injury and inflammation [2] - IL-32 is described as a lipid droplet-associated cytokine that is upregulated during tubular injury, linking lipid dysregulation, inflammation, and progression in human DKD [3] Development Plans - Over the next 12–18 months, the company plans to conduct studies to support an Investigational New Drug (IND) application with the U.S. FDA, including in vivo proof-of-concept studies targeting IL-32 for DKD treatment [4] - Arch Biopartners aims to develop next-generation drug candidates targeting IL-32 to slow or prevent the progression of chronic kidney disease in patients with diabetes and related metabolic conditions [5] Current Treatment Landscape - Current treatments for diabetic kidney disease include SGLT2 inhibitors and GLP-1 receptor agonists, which provide cardiorenal benefits but are insufficient for many patients who continue to progress to kidney failure [6] - Arch's IL-32 drug development program is among the first to directly target metabolic dysregulation-associated inflammatory signaling within the kidney, representing a new pathway to address unmet needs in chronic kidney disease treatment [7] Company Overview - Arch Biopartners is a therapeutic biotech company focused on developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD), with a pipeline that includes treatments targeting inflammation and toxin-related kidney injury [9][10]